SE0300120D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0300120D0
SE0300120D0 SE0300120A SE0300120A SE0300120D0 SE 0300120 D0 SE0300120 D0 SE 0300120D0 SE 0300120 A SE0300120 A SE 0300120A SE 0300120 A SE0300120 A SE 0300120A SE 0300120 D0 SE0300120 D0 SE 0300120D0
Authority
SE
Sweden
Prior art keywords
sup
sub
alkyl
optionally substituted
nitrogen
Prior art date
Application number
SE0300120A
Other languages
English (en)
Swedish (sv)
Inventor
Martin Cooper
Simon Guile
Tony Ingall
Rukhsana Rasul
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0300120A priority Critical patent/SE0300120D0/xx
Publication of SE0300120D0 publication Critical patent/SE0300120D0/xx
Priority to BR0406780-0A priority patent/BRPI0406780A/pt
Priority to DE602004009407T priority patent/DE602004009407T2/de
Priority to AT04702471T priority patent/ATE375352T1/de
Priority to NZ541216A priority patent/NZ541216A/en
Priority to ES04702471T priority patent/ES2293208T3/es
Priority to JP2006500749A priority patent/JP4589298B2/ja
Priority to UAA200506375A priority patent/UA80175C2/uk
Priority to MXPA05007494A priority patent/MXPA05007494A/es
Priority to CNB2004800071016A priority patent/CN100358900C/zh
Priority to EP04702471A priority patent/EP1587809B1/en
Priority to RU2005121493/04A priority patent/RU2331646C2/ru
Priority to CA002512736A priority patent/CA2512736A1/en
Priority to PL378223A priority patent/PL378223A1/pl
Priority to AU2004205617A priority patent/AU2004205617B2/en
Priority to US10/542,194 priority patent/US7064126B2/en
Priority to PCT/SE2004/000051 priority patent/WO2004065393A1/en
Priority to KR1020057013124A priority patent/KR20050092759A/ko
Priority to HK06102160.4A priority patent/HK1081958B/en
Priority to IL169363A priority patent/IL169363A/en
Priority to ZA200505273A priority patent/ZA200505273B/xx
Priority to IS7982A priority patent/IS2503B/is
Priority to NO20053827A priority patent/NO20053827L/no
Priority to US11/447,343 priority patent/US20060223809A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
SE0300120A 2003-01-17 2003-01-17 Novel compounds SE0300120D0 (sv)

Priority Applications (24)

Application Number Priority Date Filing Date Title
SE0300120A SE0300120D0 (sv) 2003-01-17 2003-01-17 Novel compounds
HK06102160.4A HK1081958B (en) 2003-01-17 2004-01-15 Thienopyridazinone derivative as modulators of autoimmune diseases
EP04702471A EP1587809B1 (en) 2003-01-17 2004-01-15 Thienopyridazinone derivative as modulators of autoimmune diseases
CA002512736A CA2512736A1 (en) 2003-01-17 2004-01-15 Novel compounds
AT04702471T ATE375352T1 (de) 2003-01-17 2004-01-15 Thienopyridazinon-derivate als modulatoren von autoimmunkrankheiten
NZ541216A NZ541216A (en) 2003-01-17 2004-01-15 Thienopyridazinone derivatives as modulators of autoimmune diseases
ES04702471T ES2293208T3 (es) 2003-01-17 2004-01-15 Derivados de tienopiridazinona como moduladores de enfermedades autoinmunes.
JP2006500749A JP4589298B2 (ja) 2003-01-17 2004-01-15 新規化合物
UAA200506375A UA80175C2 (en) 2003-01-17 2004-01-15 Thienopyridazinones, process for their preparation and their use in the modulation of autoimmune disease
MXPA05007494A MXPA05007494A (es) 2003-01-17 2004-01-15 Nuevos compuestos.
CNB2004800071016A CN100358900C (zh) 2003-01-17 2004-01-15 新化合物
BR0406780-0A BRPI0406780A (pt) 2003-01-17 2004-01-15 Novos compostos
RU2005121493/04A RU2331646C2 (ru) 2003-01-17 2004-01-15 Новые соединения
DE602004009407T DE602004009407T2 (de) 2003-01-17 2004-01-15 Thienopyridazinon-derivate als modulatoren von autoimmunkrankheiten
PL378223A PL378223A1 (pl) 2003-01-17 2004-01-15 Nowe związki
AU2004205617A AU2004205617B2 (en) 2003-01-17 2004-01-15 Novel compounds
US10/542,194 US7064126B2 (en) 2003-01-17 2004-01-15 Compounds
PCT/SE2004/000051 WO2004065393A1 (en) 2003-01-17 2004-01-15 Novel compounds
KR1020057013124A KR20050092759A (ko) 2003-01-17 2004-01-15 신규 화합물
IL169363A IL169363A (en) 2003-01-17 2005-06-23 Thienopyridazinones, processes for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
ZA200505273A ZA200505273B (en) 2003-01-17 2005-06-29 Novel compound
IS7982A IS2503B (is) 2003-01-17 2005-08-15 Ný efnasambönd
NO20053827A NO20053827L (no) 2003-01-17 2005-08-15 Nye forbindelser.
US11/447,343 US20060223809A1 (en) 2003-01-17 2006-06-06 Novel compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300120A SE0300120D0 (sv) 2003-01-17 2003-01-17 Novel compounds

Publications (1)

Publication Number Publication Date
SE0300120D0 true SE0300120D0 (sv) 2003-01-17

Family

ID=20290155

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300120A SE0300120D0 (sv) 2003-01-17 2003-01-17 Novel compounds

Country Status (22)

Country Link
US (2) US7064126B2 (https=)
EP (1) EP1587809B1 (https=)
JP (1) JP4589298B2 (https=)
KR (1) KR20050092759A (https=)
CN (1) CN100358900C (https=)
AT (1) ATE375352T1 (https=)
AU (1) AU2004205617B2 (https=)
BR (1) BRPI0406780A (https=)
CA (1) CA2512736A1 (https=)
DE (1) DE602004009407T2 (https=)
ES (1) ES2293208T3 (https=)
IL (1) IL169363A (https=)
IS (1) IS2503B (https=)
MX (1) MXPA05007494A (https=)
NO (1) NO20053827L (https=)
NZ (1) NZ541216A (https=)
PL (1) PL378223A1 (https=)
RU (1) RU2331646C2 (https=)
SE (1) SE0300120D0 (https=)
UA (1) UA80175C2 (https=)
WO (1) WO2004065393A1 (https=)
ZA (1) ZA200505273B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
MXPA05007495A (es) * 2003-01-17 2005-09-21 Astrazeneca Ab Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes.
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US7846941B2 (en) 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
ES2559521T3 (es) * 2006-10-16 2016-02-12 Thesan Pharmaceuticals, Inc. Pirazolil tienopiridinas terapéuticas
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
JP2010514695A (ja) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法およびそのための適応症
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9200005B2 (en) * 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
PL3060562T3 (pl) * 2013-10-21 2022-01-10 Genosco Podstawione związki pirymidynowe i ich zastosowanie jako inhibitory syk

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620860A1 (de) * 1986-06-21 1987-12-23 Basf Ag Substituierte acrylsaeureester und fungizide, die diese verbindungen enthalten
WO1999029695A1 (en) * 1997-12-05 1999-06-17 Astrazeneca Uk Limited Novel compounds
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
DE69912618T2 (de) * 1998-08-28 2004-10-28 Astrazeneca Ab NEUE THIENO[2,3-d]PYRIMIDINDIONE, VERFAHREN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG IN DER THERAPIE
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
MXPA05007495A (es) * 2003-01-17 2005-09-21 Astrazeneca Ab Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes.
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
CN100358900C (zh) 2008-01-02
WO2004065393A1 (en) 2004-08-05
JP4589298B2 (ja) 2010-12-01
IS7982A (is) 2005-08-15
IL169363A0 (en) 2007-07-04
IS2503B (is) 2009-04-15
ATE375352T1 (de) 2007-10-15
ZA200505273B (en) 2006-04-26
US20060052380A1 (en) 2006-03-09
DE602004009407T2 (de) 2008-07-24
JP2006515373A (ja) 2006-05-25
MXPA05007494A (es) 2005-09-21
IL169363A (en) 2011-02-28
NO20053827D0 (no) 2005-08-15
BRPI0406780A (pt) 2006-01-17
DE602004009407D1 (de) 2007-11-22
NO20053827L (no) 2005-10-17
US7064126B2 (en) 2006-06-20
KR20050092759A (ko) 2005-09-22
ES2293208T3 (es) 2008-03-16
RU2005121493A (ru) 2006-02-20
HK1081958A1 (en) 2006-05-26
RU2331646C2 (ru) 2008-08-20
EP1587809B1 (en) 2007-10-10
EP1587809A1 (en) 2005-10-26
AU2004205617A1 (en) 2004-08-05
PL378223A1 (pl) 2006-03-20
UA80175C2 (en) 2007-08-27
CN1761670A (zh) 2006-04-19
NZ541216A (en) 2008-05-30
AU2004205617B2 (en) 2007-03-08
US20060223809A1 (en) 2006-10-05
CA2512736A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
SE0300120D0 (sv) Novel compounds
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
IS2598B (is) Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma
HUP0401009A2 (hu) 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
EA200600892A1 (ru) Новые хинолиновые производные
ATE334988T1 (de) Thieno 2,3-döpyrimidinediones als inhibitoren von t-zellen-proliferation
DE69406649D1 (de) N-alkyl-2-substituierte atp-analoge
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
PE20030257A1 (es) Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4
HUP0500543A2 (hu) Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
AR012593A1 (es) Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento
BR0010366A (pt) Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
EA200001101A1 (ru) НОВЫЕ ДИГИДРОФУРО[3,4-b]ХИНОЛИН-1-ОНЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
DE60226971D1 (de) Corticotropinfreisetzungsfaktor antagonisten
ATE452636T1 (de) 3-azabicycloä4.1.0üheptan-derivate zur behandlung von depressionen
NZ535183A (en) Fused bicyclic pyrimidine derivatives
SE0400440D0 (sv) Novel Cinnamic Amides
DE60239324D1 (de) Phenyl- und pyridyl-piperidine mit tnf-wirkung
ECSP034870A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6